News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–42
Matches
42
Sources here
4
Companies here
1
Search results Stored financial headlines

Active search

42 matching headlines

Ticker or company: IMNNMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Market update Main company 🇺🇸 United States

Imunon, Inc. (IMNN) chair receives 4,603-share stock salary grant

Imunon, Inc.'s executive chairman, Michael H. Tardugno, received a grant of 4,603 shares of common stock on July 17, 2026, as compensation in lieu of a cash base salary. The shares were valued at $1.83 each. Following this transaction, Tardugno directly holds 68,999 shares …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Imunon (IMNN) grants stock in lieu of salary to CMO

Imunon, Inc. (IMNN) granted 3,082 shares of common stock to Chief Medical Officer Douglas Vincent Faller on July 17, 2026, as part of his compensation package. These shares, valued at $1.83 each, were provided in lieu of a portion of his base salary. Following …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Balance sheet Main company 🇺🇸 United States

Imunon (IMNN) CEO awarded stock instead of cash salary portion

Imunon, Inc.'s President and CEO, Stacy Lindborg, received a grant of 4,907 shares of common stock on July 17, 2026, valued at $1.83 per share. This stock award was issued in lieu of a portion of her cash base salary. Following this transaction, Lindborg …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Regulatory and legal Main company 🇺🇸 United States

IMUNON reports preliminary Phase 2 data for ovarian cancer drug

IMUNON, Inc. (NASDAQ:IMNN) has reported preliminary Phase 2 data for its investigational drug IMNN-001 in advanced ovarian cancer staged for primary debulking surgery. The data indicates a lower minimal residual disease-positive rate and higher circulating tumor DNA clearance in patients treated with IMNN-001 compared …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pluang Earnings Main company 🇺🇸 United States

IMUNON's IMNN-001 shows promising Phase 2 ovarian cancer data with improved disease clearance and safety.

IMUNON, Inc. announced positive preliminary Phase 2 data for its DNA-mediated immunotherapy IMNN-001 in advanced ovarian cancer. The study showed lower minimal residual disease rates and higher circulating tumor DNA clearance, along with a favorable safety profile. These results support IMNN-001's potential to improve …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Earnings Main company 🇺🇸 United States

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

IMUNON announced positive preliminary Phase 2 clinical data for its IMNN-001 immunotherapy in newly diagnosed advanced ovarian cancer. The study, conducted in partnership with Break Through Cancer, showed a lower minimal residual disease (MRD)-positive rate, higher circulating tumor DNA (ctDNA) clearance, and a highly …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context